Checkpoint Capital L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001977548

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 6 positions · Total reported value $389.76M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 2 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Checkpoint Capital L.P. disclosed 6 equity positions with a combined reported value of $389.76M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RYTM ($131.68M), ARGX ($121.80M), RVMD ($76.85M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+0.5pp) and away from Other (-0.5pp).

Versus the prior quarter, Checkpoint Capital L.P. opened 2 new positions, trimmed 0 and fully exited 0, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 75% of names.

Of the 2 positions fully exited versus the prior quarter, the largest were SEPN ($2.41M), CRNX ($1.46M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • SEPN SEPTERNA INC · prev qtr: $2.41M · history
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $1.46M

Insider Transactions (Form 4)

Latest Checkpoint Capital L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Checkpoint Capital L.P., based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $389.76M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-134055 (status: Approved), registered 2025-08-19
  • Regulatory AUM (Form ADV): $333.78M as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: checkpointlp.com

Portfolio Structure

  • 6 positions · $389.76M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: RYTM (RHYTHM PHARMACEUTICALS INC) at 33.8%
  • Average position size: $64.96M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 added, 3 reduced, 2 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Checkpoint Capital L.P. appears to be maintaining a cautious approach with a focus on rebalancing within the healthcare sector. The reduction in positions and the increase in some healthcare stocks suggest a preference for selective growth within the industry. 2. Key Moves: - Added: Revolution Medicines Inc. (RVMD) and Cytokine Therapeutics Inc. (CYTK), indicating a belief in their potential for growth. - Reduced: Rhythm Pharmaceuticals Inc. (RYTM) and Argenx SE (ARGX), possibly due to concerns about their current valuations or market performance. - Reduced: Disc Medicine Inc. (IRON), likely due to a reassessment of its potential or market dynamics. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be more active, as evidenced by the significant changes in holdings and the addition of new positions. - Sector Bias: A strong bias towards healthcare, with over 70% of the portfolio value in healthcare-related investments. - Risk Appetite: The fund shows a moderate risk appetite, with the addition of high-growth potential stocks but also the reduction of positions in more established companies. 4. Per-Holding One-Liner: - RYTM: Rhythm Pharmaceuticals Inc. - Specializes in the development of treatments for rare genetic diseases, particularly in the field of metabolic disorders. 'Unverified' - ARGX: Argenx SE - A biotechnology company focused on the development of therapies for cancer and rare diseases. 'Unverified' - RVMD: Revolution Medicines Inc. - Focuses on the development of novel cancer therapies, including those targeting the PI3K/mTOR pathway. 'Unverified' - CYTK: Cytokine Therapeutics Inc. - Engaged in the development of treatments for cancer and autoimmune diseases. 'Unverified' - IRON: Disc Medicine Inc. - A biopharmaceutical company focused on the development of therapies for neurological disorders. 'Unverified' - TRVI: Trevi Therapeutics Inc. - Specializes in the development of therapies for central nervous system disorders, including pain and neurodegenerative diseases. 'Unverified' 5. One-Sentence Style Summary: Checkpoint Capital L.P. selectively rebalanced its healthcare-focused portfolio this quarter, adding high-growth potential stocks while reducing exposure to more established companies, reflecting a cautious yet growth-oriented strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.19M $131.68M 33.78%
33.78%
Reduce
2 131.28K $121.80M 31.25%
31.25%
Reduce
3 410.35K $76.85M 19.72%
19.72%
Add
4 475.00K $40.47M 10.38%
10.38%
Add
5 240.12K $17.56M 4.51%
4.51%
Reduce
6 75.00K $1.40M 0.36%
0.36%
Add

FAQ

What did Checkpoint Capital L.P. buy in 2026-Q2?

In its 2026-Q2 13F filing, Checkpoint Capital L.P. reported 6 equity positions worth $389.76M in aggregate; its largest disclosed positions were RYTM ($131.68M), ARGX ($121.80M), RVMD ($76.85M).

How large is Checkpoint Capital L.P.'s portfolio?

Checkpoint Capital L.P. reported $389.76M of long equity holdings across 6 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Checkpoint Capital L.P.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/checkpoint-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →